Assessment of tumor hypoxia in laryngeal cancer with 18F-fluoroazomycin arabinoside (18F-FAZA)-PET/CT scanning, oxygen-enhanced MRI (OE-MRI) and immunohistochemistry

Assessment of tumor hypoxia in laryngeal cancer with 18F-fluoroazomycin arabinoside (18F-FAZA)-PET/CT scanning, oxygen-enhanced MRI (OE-MRI) and immunohistochemistry - 18F-FAZA-PET and OE-MRI in laryngeal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33970

Enrollment

Registered

2009-06-19

Start date

2010-02-15

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

laryngeal cancer vocal cord cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Patients with primary or recurrent squamous cell carcinoma of the larynx in whom total laryngectomy is considered the treatment of choice. * Glottic, subglottic or supraglottic larynxcarncer * Tumor volume more than 2 cm3 * WHO performance: 0-2 * Patients older than 18 years * Written informed consent

Exclusion criteria

Exclusion criteria: * Patient who does not sign the consent * Pregnancy * Patients younger than 18 years * Contraindications MRI, as o Pacemakers / ICD's (cochlear implant, baclofenpump, insulin-pump o Severe renal insufficiency (eGFR

Design outcomes

Primary

Measure	Time frame
Preoperative hypoxia data acknowledged by 18F-FAZA-PET/CT and OE-MRI scan are compared with immunohistochemical results.	—

Secondary

Measure	Time frame
No	—

Countries

Netherlands

Outcome results